Zhangguo Hu1, Xiang Gu2, Runbo Zhong1, Hua Zhong1. 1. Department of Pulmonary Disease, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China. 2. Department of Emergency, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.
Abstract
BACKGROUND: The present study aimed to investigate the association of CD45RO+, CD8+, CCR7+ and FOXP3+ tumor-infiltrating lymphocytes (TILs) with the clinicopathological features as well as survival of patients with lung adenocarcinoma. METHODS: Ninety patients with lung adenocarcinoma who underwent surgery were recruited in the present study. Lung adenocarcinoma tissues and paired adjacent lung tissues were obtained from all participants, and immunohistochemistry was performed to detect the expression of CD45RO, CD8, CCR7 and FOXP3. After multiplying the staining intensity score by the labeling frequency score, the immunohistochemical results were divided into three groups: TILs low, TILs intermediate and TILs high. RESULTS: CD45RO+, CD8+ and CCR7+ infiltrating lymphocytes were markedly increased in lung adenocarcinoma (all P<0.001) while FOXP3+ infiltrating lymphocytes were reduced (P<0.001) compared with than in adjacent tissues. CD45RO+ TILs were negatively associated with tumor size (P=0.002), lymph node metastasis (P<0.001) and TNM stage (P<0.001). CD8+ TILs were also negatively correlated with lymph node metastasis (P=0.016). Kaplan-Meier curve analysis revealed that CD45RO+ TILs were positively associated with longer disease-free survival (DFS) (P<0.001) and overall survival (OS) (P<0.001). Univariate and multivariate Cox's proportional hazards regression confirmed that CD45RO+ TILs (high) independently predicted longer DFS (P=0.002) and OS (P=0.009). CONCLUSIONS: The present study demonstrates that CD45RO+ TILs are negatively correlated with tumor size, lymph node metastasis and TNM stage and that CD45RO+ TILs (high) can be regarded as a novel and promising biomarker for prolonged DFS and OS in lung adenocarcinoma patients.
BACKGROUND: The present study aimed to investigate the association of CD45RO+, CD8+, CCR7+ and FOXP3+ tumor-infiltrating lymphocytes (TILs) with the clinicopathological features as well as survival of patients with lung adenocarcinoma. METHODS: Ninety patients with lung adenocarcinoma who underwent surgery were recruited in the present study. Lung adenocarcinoma tissues and paired adjacent lung tissues were obtained from all participants, and immunohistochemistry was performed to detect the expression of CD45RO, CD8, CCR7 and FOXP3. After multiplying the staining intensity score by the labeling frequency score, the immunohistochemical results were divided into three groups: TILs low, TILs intermediate and TILs high. RESULTS: CD45RO+, CD8+ and CCR7+ infiltrating lymphocytes were markedly increased in lung adenocarcinoma (all P<0.001) while FOXP3+ infiltrating lymphocytes were reduced (P<0.001) compared with than in adjacent tissues. CD45RO+ TILs were negatively associated with tumor size (P=0.002), lymph node metastasis (P<0.001) and TNM stage (P<0.001). CD8+ TILs were also negatively correlated with lymph node metastasis (P=0.016). Kaplan-Meier curve analysis revealed that CD45RO+ TILs were positively associated with longer disease-free survival (DFS) (P<0.001) and overall survival (OS) (P<0.001). Univariate and multivariate Cox's proportional hazards regression confirmed that CD45RO+ TILs (high) independently predicted longer DFS (P=0.002) and OS (P=0.009). CONCLUSIONS: The present study demonstrates that CD45RO+ TILs are negatively correlated with tumor size, lymph node metastasis and TNM stage and that CD45RO+ TILs (high) can be regarded as a novel and promising biomarker for prolonged DFS and OS in lung adenocarcinoma patients.
Authors: Y Asano; S Kashiwagi; W Goto; K Kurata; S Noda; T Takashima; N Onoda; S Tanaka; M Ohsawa; K Hirakawa Journal: Br J Surg Date: 2016-03-08 Impact factor: 6.939
Authors: Ilona Kryczek; Marian Gryboś; Dorota Dlubek; Aleksandra Klimczak; Jerzy Rabczyński; Andrzej Lange Journal: Cancer Immunol Immunother Date: 2002-09-06 Impact factor: 6.968
Authors: Roy M Bremnes; Lill-Tove Busund; Thomas L Kilvær; Sigve Andersen; Elin Richardsen; Erna Elise Paulsen; Sigurd Hald; Mehrdad Rakaee Khanehkenari; Wendy A Cooper; Steven C Kao; Tom Dønnem Journal: J Thorac Oncol Date: 2016-02-01 Impact factor: 15.609